1. Targeting TAM to Tame Pancreatic Cancer.
- Author
-
von Itzstein MS, Burke MC, Brekken RA, Aguilera TA, Zeh HJ, and Beg MS
- Subjects
- Humans, Pancreatic Neoplasms pathology, Receptor Protein-Tyrosine Kinases pharmacology, Immunotherapy methods, Molecular Targeted Therapy methods, Pancreatic Neoplasms drug therapy, Receptor Protein-Tyrosine Kinases therapeutic use
- Abstract
Pancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mechanistic investigations and therapeutic combinations in the preclinical setting suggest that TAM inhibition with chemotherapy, targeted therapy, and immunotherapy should be evaluated clinically.
- Published
- 2020
- Full Text
- View/download PDF